Reuters exclusively revealed that drugmakers including Pfizer Inc, GlaxoSmithKline PLC, Bristol Myers Squibb, AstraZeneca PLC and Sanofi SA plan to raise prices in the United States on more than 350 unique drugs in early January. The increases are expected to come as the industry prepares for the Biden Administration’s Inflation Reduction Act, which lets the government negotiate prices directly for some drugs, starting in 2026.